Connect with us

Health

1 adverse reaction reported as 490 more Manitobans receive COVID-19 vaccine – CBC.ca

Published

 on


Manitoba public health officials say 490 more people received the first dose of the COVID-19 vaccine on Wednesday, and one person had an “adverse reaction,” according to a news release issued on Christmas Eve.

The province didn’t say what kind of reaction the person had, but Health Canada has advised people with severe allergies to any of the ingredients in the Pfizer-BioNTech COVID-19 vaccine not to get it. 

That’s after two people in the U.K. went into anaphylactic shock after they were immunized earlier this month.

No other adverse reactions have been reported in the province.

A total of 2,177 immunizations have been given since the vaccine arrived in Manitoba earlier this month.

So far, only certain front-line health-care workers are eligible to receive the vaccine in Manitoba.

The province says it’s opening up criteria so more workers can get inoculated after Christmas. The workers must all still have direct contact with patients and work in certain units, but the province is scrapping the age requirement for workers in critical care.

Other eligible workers must meet one of the following criteria:

  • Work in long-term care facilities and be born on or before Dec. 31, 1962.
  • Work in acute care facilities and be born on or before Dec. 31, 1962.
  • Be assigned to a COVID-19 immunization clinic or testing site.

The province says 500 more appointments for vaccinations are available following Christmas. The clinic will reopen on Dec. 29 and 30 and vaccinate approximately 900 people.

Starting in the new year, a broader swath of health-care workers — including paramedics and those who work in home care — will be eligible for innoculation.

The vaccine requires two doses; the second doses will be administered at the RBC Convention Centre site in three weeks, health officials have said. 

The first shots will be given out at the University of Manitoba’s Bannatyne campus, adjacent to Health Sciences Centre. That site was chosen because it has the capacity to store the Pfizer-BioNTech vaccine, which must be kept at ultra-low temperatures.

Let’s block ads! (Why?)



Source link

Continue Reading

Health

Calgary company begins clinical trials for Canadian-made COVID vaccine candidate – HalifaxToday.ca

Published

 on


A prospective COVID-19 vaccine touted as a made-in-Canada response has begun human clinical trials in Toronto, and the company says it’s already preparing a followup that will target more infectious variants.

Providence Therapeutics of Calgary says if all goes well, it could start manufacturing millions of doses of its first prospective vaccine by the end of the year, guaranteeing a Canadian stockpile that wouldn’t be subject to global supply pressures or competition.

That’s if the formulation proves safe and effective, of course. 

Among the challenges of developing a vaccine amid a raging pandemic is the uncertainty of how more infectious variants now emerging will complicate the COVID battle. 

Even if successful, by the time Providence Therapeutics releases its vaccine hopeful, much of the country could be in the throes of a more infectious virus that does not respond to this formulation, said company CEO Brad Sorenson. 

“We don’t believe that this is going to be resolved by a single vaccine,” said Sorenson, whose biotech also produces a personalized mRNA-based vaccine against cancer.

It’s a challenge now facing Pfizer-BioNTech and Moderna, which have each said its products appear to respond well to the variant initially identified in the United Kingdom, and to a lesser degree, the variant first detected in South Africa.

Moderna said earlier this week it plans to test two booster vaccines aimed at the variant associated with South Africa.

Sorenson said Providence is already internally testing a vaccine candidate that targets the variants, and he hoped to begin clinical trials by the end of the year.

“We believe that there’s going to be a need to be in a position of readiness to be able to respond as these variants are coming up, and to be able to make sure that we have that capacity.”

That doesn’t mean Providence is changing production runs just yet. 

Sorenson said the immediate focus is to establish the safety and efficacy of its COVID-19 vaccine, dubbed PTX-COVID19-B and designed in the early days of the pandemic last March.

It uses messenger RNA technology and focuses on the spike protein located on the surface of a coronavirus that initiates infection, similar to the Pfizer-BioNTech and Moderna products.

The trial involves 60 healthy volunteers aged 18 to 25 who will be monitored for 13 months, with the first results expected in February. 

The subjects are divided into four groups of 15, three of which will get three different doses. The fourth group gets a placebo.

Sorenson said immediate pandemic efforts should be focused on the novel coronavirus currently devastating many parts of the country.

“It’s a matter of capacity. Right now these variants are there, they’re concerning, and we’re keeping a close eye on it, but that’s not predominantly what the needs of the population are,” said Sorenson.

“Right now the needs of the population are still tied to the primary spike protein virus that’s out there and is ravaging around the world.”

Sorenson said his next vaccine candidate takes a broader approach by attempting to elicit a T-cell response, thereby creating a longer-term vaccine “and cover what we believe would be a lot more variants.”

“We have to prove it out, but we believe that if we are successful that it will allow for a much more durable immunity and a much broader immunity.”

The other goal is to prepare for large-scale manufacturing in Calgary, if all goes well with the trials and approval process.

Sorenson said doses for the Phase 1 trial are being made in Toronto, but the plan is to commercially manufacture the completed vaccine through a contract with the Calgary-based Northern RNA Inc.

That won’t be up and running by the end of the year, Sorenson allowed, so the short-term plan is to send raw materials made in Canada to a plant in the United States that would make the commercial product.

Eventually, the whole process would be completed in Canada, he said.

“We’re building the entire chain within Canada, so we’re not going to run into a problem where this particular input into the vaccine is unavailable,” he said.

Much of this also depends on financial support from the federal government, Sorenson added.

While the National Research Council of Canada has backed Phase 1 trials, Sorenson said he’s awaiting word on further support. He’d also like Ottawa to back Providence’s efforts to address the new COVID variants.

“They’ve already recognized the importance of mRNA technology. What they don’t realize is the power of mRNA technology to be responsive to these challenges that are coming up,” he said.

“Hopefully the politicians and the people that cut the cheques and write the policies that give direction to the bureaucrats will hear that and we’ll start seeing a more concerted approach that looks at a fuller picture.”

Pending regulatory approval, Sorenson said a larger, international Phase 2 trial may start in May with seniors, younger subjects and pregnant people, followed by an even broader Phase 3 trial.

The Providence project is just one of several Canadian efforts underway to develop a COVID-19 vaccine. 

The biopharmaceutical company Medicago, based in Quebec City, began clinical trials on its plant-based candidate last July. If successful, the company has said manufacturing would take place in Durham, N.C., until it can complete a large-scale manufacturing facility set for Quebec City.

And last month, Health Canada gave the green light to the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan to launch its Phase 1 clinical vaccine trial.

Infectious disease expert Jason Kindrachuk, who works with VIDO but is not involved with its vaccine candidate, said a varied vaccine strategy will be key to controlling the pandemic. 

“Vaccines are not necessarily a one-size-fits-all and maybe with this pandemic, people are getting a greater appreciation for some of the logistical hurdles of trying to transport vaccines. Cold chain storage is not something most people knew about or thought about prior to COVID and everybody in the community now I think has heard about it,” said Kindrachuk, a visiting scientist from the University of Manitoba and Canada Research Chair.

“This is something that, in regards to vaccine development, we really have to put a lot of thought into as a research community because of the fact that we have to make vaccines that are accessible for the communities that are ultimately going to be treated with them.”

Ontario Health Minister Christine Elliott acknowledged Tuesday that appetite was strong for a homegrown answer but noted Providence was still a considerable ways from offering a viable option.

“First it has to go through the appropriate approval process, go through Health Canada to make sure that it’s going to be satisfactory and safe and efficacious,” said Elliott.

This report by The Canadian Press was first published Jan. 26, 2021.

Cassandra Szklarski, The Canadian Press

Let’s block ads! (Why?)



Source link

Continue Reading

Health

COVID-19: What you need to know for January 27 – TVO

Published

 on


This article was last updated on Wednesday at 10:32 a.m.

  • According to data as of January 25, there are 745 new cases in Toronto, for a total of 83,474 since the pandemic began; six of them are in hospital. In total, six people have died.
  • Dr. Charles Gardner, medical officer of health for the Simcoe Muskoka District Health Unit (SMDHU), said data from Public Health Ontario suggests that the COVID-19 variant is now present in the Waypoint Centre for Mental Health Care, formerly known as Mental Health Centre Penetanguishene, reports CBC. Further testing is still required to confirm if the variant is one first detected in the United Kingdom.

  • Canada Post has said that customers “should expect delays with their parcels” as a result of the COVID-19 outbreak at a facility in Mississauga, reports CP24. In a statement released on Tuesday afternoon, Canada Post said that they are aware of 224 positive cases at their Gateway facility since January 1, including a dozen that have come to light over the last 24 hours.

  • 22 support staff at Beverly School, a public school in Toronto’s downtown that serves students with developmental and physical disabilities, are refusing to work for a second consecutive day due to concerns about their safety amid the COVID-19 pandemic, reports CTV News. The Toronto District School Board has confirmed that there have been a total of five positive COVID-19 cases at Beverly School, one involving a student, one involving a staff member and three involving bus drivers.

  • Starting next month, Toronto will close its outdoor skating rinks to out-of-towners, reports the Toronto Star.The city’s park, forestry and recreation division said Tuesday that it had received “a number of complaints” to its customer service phone lines over the holidays about non-Torontonians making skate reservations online.
  • On Tuesday, Hamilton recorded eight new COVID deaths and a record-high 53 active outbreaks, reports the Hamilton Spectator. Of the city’s 53 outbreaks, more than half are in retirement homes, long-term-care homes and hospitals, six are in workplaces, four are in shelters and two are in daycares.

  • In reponse to reporting by the Hamilton Spectator on the tragic conditions workers at the Grave Villa long-term-care home, APANS Health Services, which operates the home has said, “the safety of our residents, staff and family members is paramount and these statements are deeply concerning,” said CEO Mary Raithby to the newspaper. Workers at the home sent letters and emails to their local MPP’s detailing conditions at the home, which has become the site of Hamilton’s deadliest outbreak.

  • Hospitals in Hamilton won’t say how many staff go vaccinated sooner than they should have. As the Hamilton Spectator reports, staff were able to evaluate which priority group they fell into, thus determining when they would get their first dose. Hamilton Health Sciences and St. Joseph’s Healthcare both say most staff registered correctly, but would not confirm how many people did not. The paper also reports that Hamilton’s medical officer of health, Dr. Elizabeth Richardson, could not say on Monday how many staff or residents are left to vaccinate in long-term care homes, or how many people in Hamilton have been vaccinated overall. She said that while staff know who has been vaccinated, Ontario’s system does not allow for a breakdown of the numbers.
  • Let’s block ads! (Why?)



    Source link

    Continue Reading

    Health

    China, India's COVID-19 vaccinations to stretch to late 2022 – study – The Guardian

    Published

     on


    SINGAPORE (Reuters) – COVID-19 vaccination programmes in China and India will stretch until late 2022 due to the sheer size of their population, and more than 85 poor countries will not have widespread access to vaccines before 2023, a study showed on Wednesday.

    While rapid development of vaccines has raised hopes for an end to the year-long pandemic, concerns over unequal distribution have also mounted due to production problems and large bilateral deals between wealthy countries and drug makers.

    U.S. President Joe Biden said on Tuesday that the United States aims to secure an additional 200 million doses of COVID-19 vaccines from Pfizer and its partner BioNTech and Moderna Inc by summer.

    In Europe, the European Commission is setting up a proposal to restrict COVID-19 vaccine exports amid frustration over delays in deliveries of AstraZeneca’s vaccine and other supply problems.

    “Most developing countries will not have widespread access to the shots before 2023 at the earliest,” Agathe Demarais, director of the Economist Intelligence Unit, the research division of the Economist Group, said in its study.

    “Some of these countries—particularly poorer ones with a young demographic profile—may well lose the motivation to distribute vaccines, especially if the disease has spread widely or if the associated costs prove too high.”

    Most countries in Africa are unlikely to get widespread vaccination coverage until early 2023, while many Asian countries will have broad access to vaccines by late 2022.

    The report said vaccine deliveries to poor countries by global vaccine sharing scheme COVAX, backed by the World Health Organization, may be slow due to delays in delivery to wealthy nations first and poor infrastructure in the developing world.

    COVAX said 1.8 billion doses would be supplied to 92 poorer countries in 2021 and that would correspond to approximately 27% coverage of populations in those countries.

    (Reporting by Miyoung Kim; Editing by Michael Perry)

    Let’s block ads! (Why?)



    Source link

    Continue Reading

    Trending